DB05493InvestigationalSmall molecule
NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic...
- Mechanism
- Curator reviewed
NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed.
- Primary indication
- Investigated for use/treatment in benign prostatic hyperplasia.Curator reviewed
- Code names
- NX-1207
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of October 27, 2025
Which companies are running trials of Fexapotide, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account